-
Study aim
-
Investigation the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia- A Phase 2&3 Clinical Trial
-
Design
-
Clinical trial with control group, with parallel groups, without blinding, randomized, phase 3 and 2 on 120 patients. A simple randomization method is used for randomization.
-
Settings and conduct
-
This study is performed in the field of infectious diseases. It is located in Afzalipour Hospital and the Comprehensive Center for Stem Cells and Regenerative Medicine of Kerman University of Medical Sciences. In this study, 2 groups are intervened. Both groups receive conventional therapies. In addition, in the first group, patients have oxygen masks and receive stem cells, and in the second group, patients receive intubation and receive mesenchymal stem cells.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
Patients aged between 18-95 years
Patients Approved for Covirus 19 by Laboratory Methods
Patients with mild to moderate respiratory distress
Hospitalization in the ICU
Exclusion criteria:
Patients undergoing other clinical trials
Patients with underlying diseases including diabetes, heart disease, respiratory disease, cancer patients and patients undergoing chemotherapy
-
Intervention groups
-
Two groups of patients are involved in this study. The first group uses an oxygen mask. The second group is patients admitted to the ICU who are intubated. Both groups receive mesenchymal stem cells in addition to conventional therapies. In addition to these two intervention groups, there are two control groups, the first group receiving only oxygen masks and conventional therapies, and the second group of patients admitted to the ICU receiving only conventional therapies.
-
Main outcome variables
-
Pulmonary condition, RNA expression of COVID19 virus, Lymphocytes count, Study of clinical signs